ArticleMicroorganisms2021
Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.
Open access · goldAbstract read
In one paragraph
Article in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Serotype distribution of invasive and non-invasive pneumococcal disease in children ≤5 years of age following the introduction of 10- and 13-valent pneumococcal conjugate vaccines in infant national immunization programs: a systematic literature review.Frontiers in public health · 2025Pooled it
- Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021.Frontiers in public health · 2024Pooled it
- The impact of pneumococcal conjugate vaccines on disease epidemiology, serotype distribution, and antimicrobial resistance in children. A 25-year observational study in Athens, Greece (1996-2021).Human vaccines & immunotherapeutics · 2026Observational
- Surveillance of invasive pneumococcal disease in Germany: surge in PCV13 serotypes and new challenges, 2017 to 2024.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Disease burden of Streptococcus pneumoniae and Neisseria meningitidis meningitis in children and adolescents: A population-based study.Medicine · 2026Article
- Invasive Pneumococcal Disease Epidemiology and Conjugate Vaccines in Canada, 2000-2019.JAMA network open · 2026Article
- Long-Term Impact of Pneumococcal Conjugate Vaccines on the Burden of Pneumococcal Meningitis in Mozambique, 2013-2023.Vaccines · 2025Article
- Toward Universal Protection: A Comprehensive Review of Pneumococcal Disease, Emerging Vaccination Challenges and Future Perspectives.Vaccines · 2025Review
- Review
- Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999-2019).The Journal of antimicrobial chemotherapy · 2025Article
- Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review.Vaccines · 2025Review
- Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis.The Lancet. Infectious diseases · 2025Article
- Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis.The Lancet. Infectious diseases · 2025Article
- Review
- Update on the evolving landscape of pneumococcal capsule types: new discoveries and way forward.Clinical microbiology reviews · 2025Review
- Global impact of 10- and 13-valent pneumococcal conjugate vaccines on pneumococcal meningitis in all ages: The PSERENADE project.The Journal of infection · 2025Article
- A decade of 10-valent pneumococcal conjugate vaccine use in Lithuania: trends in invasive pneumococcal serotype dynamics.Frontiers in public health · 2025Article
- Bridging the gap in pneumonia prevention: Qualitative insights on vaccine implementation from health leaders in middle-income countries.PLOS global public health · 2025Article
- Sustainability of pneumococcal conjugate vaccination in Ghana: a cost-effectiveness analysis in the context of donor transition.Frontiers in public health · 2024Article
- Serotype distribution, clinical characteristics, and antimicrobial resistance of pediatric invasive pneumococcal disease in Colombia during PCV10 mass vaccination (2017-2022).Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
73 authors at 20 institutions in 43 countries.
Maria Deloria KnollJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0001-9041-2671
Julia C BennettJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0003-2559-2922
Maria Garcia QuesadaJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0002-0206-7597
Eunice W KaguciaEpidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya.
Meagan E PetersonJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0001-6562-2730
Daniel R FeikinIndependent Consultant, 1296 Coppet, Switzerland.
Adam L CohenWorld Health Organization, 1202 Geneva, Switzerland.
Marissa K HetrichJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Yangyupei YangJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Jenna N SinkevitchJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Krow AmpofoDivision of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT 84132, USA.
Laurie AukesVaccine Study Center, Kaiser Permanente, Oakland, CA 94612, USA.
Sabrina BacciEuropean Centre for Disease Prevention and Control, 169 73 Solna, Sweden.
Godfrey BigogoCentre for Global Health Research, Kenya Medical Research Institute, P.O. Box 1578-40100, Kisumu, Kenya.
Maria-Cristina C BrandileoneNational Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz (IAL), São Paulo 01246-902, Brazil.ORCID 0000-0002-7254-9102
Michael G BruceArctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK 99508, USA.ORCID 0000-0001-8275-3484
Romina CamilliDepartment of Infectious Diseases, Italian National Institute of Health (Istituto Superiore di Sanità, ISS), 00161 Rome, Italy.
Jesús CastillaCIBER Epidemiología y Salud Pública, (CIBERESP), 28029 Madrid, Spain.ORCID 0000-0002-6396-7265
Guanhao ChanSingapore Ministry of Health, Communicable Diseases Division, Singapore 308442, Singapore.
Grettel Chanto ChacónInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Tres Ríos, 30301 Cartago, Costa Rica.
Pilar CiruelaCIBER Epidemiología y Salud Pública, (CIBERESP), 28029 Madrid, Spain.ORCID 0000-0003-0842-7220
Heather CookCentre for Disease Control, Department of Health and Community Services, Darwin City, NT 8000, Australia.
Mary CorcoranIrish Meningitis and Sepsis Reference Laboratory, Children's Health Ireland at Temple Street, Temple Street, D01 YC76 Dublin 1, Ireland.ORCID 0000-0002-6669-9083
Ron DaganThe Faculty of Health Sciences, Ben-Gurion University of the Negev, 8410501 Beer-Sheva, Israel.
Kostas DanisSanté Publique France, the French National Public Health Agency, FR-94410 Saint Maurice, France.
Sara de MiguelEpidemiology Department, Dirección General de Salud Pública, 28009 Madrid, Spain.
Philippe De WalsDepartment of Social and Preventive Medicine, Laval University, Québec, QC G1V 0A6, Canada.
Stefanie DesmetDepartment of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
Yvonne GallowayEpidemiology Team, Institute of Environmental Science and Research, Porirua, Wellington 5022, New Zealand.
Theano GeorgakopoulouNational Public Health Organisation, 15123 Athens, Greece.
Laura L HammittJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Markus HiltySwiss National Reference Centre for invasive Pneumococci, Institute for Infectious Diseases, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0002-2418-6474
Pak-Leung HoDepartment of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China.ORCID 0000-0002-8811-1308
Sanjay JayasingheNational Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia.
James D KellnerDepartment of Pediatrics, University of Calgary, and Alberta Health Services, Calgary, AB T3B 6A8, Canada.
Jackie KleynhansCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa.ORCID 0000-0001-7081-6273
Mirjam J KnolNational Institute for Public Health and the Environment, 3721 MA Bilthoven, The Netherlands.
Jana KozakovaNational Institute of Public Health (NIPH), 100 42 Praha, Czech Republic.
Karl Gústaf KristinssonDepartment of Clinical Microbiology, Landspitali-The National University Hospital, Hringbraut, 101 Reykjavik, Iceland.
Shamez N LadhaniImmunisation and Countermeasures Division, Public Health England, London NW9 5EQ, UK.
Claudia S LaraServicio de Bacteriología Clínica, Departamento de Bacteriología, INEI-ANLIS "Dr. Carlos G. Malbrán", Buenos Aires C1282 AFF, Argentina.
Maria Eugenia LeónLaboratorio Central de Salud Pública, Asunción, Paraguay (Central Laboratory of Public Health, Asunción, Paraguay), Asunción, Paraguay.
Tiia LeppDepartment of Communicable Disease and Control and Health Protection, Public Health Agency of Sweden, 171 82 Solna, Sweden.
Grant A MackenzieFaculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, Keppel St, London WC1E 7HT, UK.
Lucia Mad'arováNational Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, 975 56 Banská Bystrica, Slovakia.ORCID 0000-0001-8546-395X
Allison McGeerToronto Invasive Bacterial Diseases Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada.
Tuya MungunNational Center of Communicable Diseases (NCCD), Ministry of Health, Bayanzurkh District, Ulaanbaatar 13336, Mongolia.
Jason M MwendaWorld Health Organization Regional Office for Africa, P.O. Box 06, Brazzaville, Congo.
J Pekka NuortiDepartment of Health Security, Finnish Institute for Health and Welfare, 00271 Helsinki, Finland.
Néhémie NzoyikoreraBacteriology-Virology and Hospital Hygiene Laboratory, Ibn Rochd University Hospital Centre, Casablanca 20250, Morocco.ORCID 0000-0002-0971-2245
Kazunori OishiToyama Institute of Health, Imizu, Toyama 939-0363, Japan.ORCID 0000-0001-5919-7520
Lucia Helena De OliveiraPan American Health Organization, World Health Organization, Washington, DC 20037, USA.
Metka ParagiCentre for Medical Microbiology, National Laboratory of Health, Environment and Food, 2000 Maribor, Slovenia.
Tamara PilishviliNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Rodrigo PuentesInstituto de Salud Pública de Chile, Santiago 7780050, Santiago Metropolitan, Chile.ORCID 0000-0001-8607-2467
Eric RafaiMinistry of Health and Medical Services, Suva, Fiji.
Samir K SahaChild Health Research Foundation, Dhaka 1207, Bangladesh.
Larisa SavrasovaCentre for Disease Prevention and Control of Latvia, 1005 Riga, Latvia.
Camelia SavulescuEpidemiology Department, Epiconcept, 75012 Paris, France.
J Anthony ScottEpidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine-Coast, P.O. Box 230-80108, Kilifi, Kenya.
Kevin J ScottBacterial Respiratory Infection Service, Scottish Microbiology Reference Laboratory, NHS GG&C, Glasgow, G31 2ER, UK.ORCID 0000-0003-3338-9967
Fatima SerhanWorld Health Organization, 1202 Geneva, Switzerland.
Lena Petrova SetchanovaDepartment of Medical Microbiology, Medical University of Sofia, Faculty of Medicine, 1431 Sofia, Bulgaria.
Nadja Sinkovec ZorkoCommunicable Diseases Centre, National Institute of Public Health, 1000 Ljubljana, Slovenia.
Anna SkoczyńskaNational Reference Centre for Bacterial Meningitis, National Medicines Institute, 00-725 Warsaw, Poland.ORCID 0000-0002-2247-830X
Todd D SwarthoutMalawi-Liverpool-Wellcome Trust Clinical Research Programme, P.O. Box 30096, Chichiri, Blantyre, Malawi.ORCID 0000-0001-5285-7039
Palle Valentiner-BranthInfectious Disease Epidemiology and Prevention, Statens Serum Institut, DK-2300 Copenhagen, Denmark.
Mark van der LindenNational Reference Center for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Didrik F VestrheimDepartment of Infection Control and Vaccine, Norwegian Institute of Public Health, 0456 Oslo, Norway.
Anne von GottbergCentre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, Johannesburg 2192, South Africa.ORCID 0000-0002-0243-7455
Inci YildirimDepartment of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT 06504, USA.ORCID 0000-0002-8631-0020
Kyla HayfordJohns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0002-9872-2313
The Pserenade Team
Johns Hopkins University · USKenya Medical Research Institute · KECenters for Disease Control and Prevention · USNational Health Laboratory Service · ZAWorld Health Organization · CHAdministración Nacional de Laboratorios e Institutos de Salud · ARAlberta Health Services · CABen-Gurion University of the Negev · ILCentre Hospitalier Universitaire Ibn Rochd · MACentro de Investigación Biomédica en Red de Epidemiología y Salud Pública · ESChild Health Research Foundation · BDEuropean Centre for Disease Prevention and Control · SEGovernment of Western Australia Department of Health · AUInstituto Adolfo Lutz · BRInstituto Costarricense de Investigación y Enseñanza en Nutrición y Salud · CRInstituto de Salud Pública de Chile · CLInstituto de Salud Pública de Navarra · ESIPS Central · PYIstituto Superiore di Sanità · ITKaiser Permanente · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MBill and Melinda Gates Foundation INV-010429 / OPP1189065NCATS NIH HHS UL1 TR001863World Health Organization 001
Abstract
Serotype-specific surveillance for invasive pneumococcal disease (IPD) is essential for assessing the impact of 10- and 13-valent pneumococcal conjugate vaccines (PCV10/13). The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) project aimed to evaluate the global evidence to estimate the impact of PCV10/13 by age, product, schedule, and syndrome. Here we systematically characterize and summarize the global landscape of routine serotype-specific IPD surveillance in PCV10/13-using countries and describe the subset that are included in PSERENADE. Of 138 countries using PCV10/13 as of 2018, we identified 109 with IPD surveillance systems, 76 of which met PSERENADE data collection eligibility criteria. PSERENADE received data from most (n = 63, 82.9%), yielding 240,639 post-PCV10/13 introduction IPD cases. Pediatric and adult surveillance was represented from all geographic regions but was limited from lower income and high-burden countries. In PSERENADE, 18 sites evaluated PCV10, 42 PCV13, and 17 both; 17 sites used a 3 + 0 schedule, 38 used 2 + 1, 13 used 3 + 1, and 9 used mixed schedules. With such a sizeable and generally representative dataset, PSERENADE will be able to conduct robust analyses to estimate PCV impact and inform policy at national and global levels regarding adult immunization, schedule, and product choice, including for higher valency PCVs on the horizon.
Indexed as
globalinvasive pneumococcal diseasepneumococcal conjugate vaccinespneumococcal meningitissurveillance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.